small+molecules - Available Technologies | Rutgers University Innovation Ventures

Search Results - small+molecules

7 Results Sort By:
Sigma-1 Receptor Antagonists – Non-Addictive Pain Management
Invention Summary: The sigma 1 receptor (S1R), a molecular chaperone protein located in the endoplasmic reticulum and plasma membranes, plays important roles in various pathological disorders including pain. The potential commercial applications of novel S1R antagonists are twofold: 1) as stand-alone therapy for the treatment of chronic neuropathic...
Published: 7/9/2021   |   Inventor(s): William Welsh, Youyi Peng
Keywords(s): Antiviral, Neurological disorder & neuropathic pain, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Novel Inhibitors of Keap1-Nrf2 Protein-Protein Interaction
Novel Small Molecule Direct Inhibitors of Keap1-Nrf2 Protein-Protein Interaction Invention Summary: Nrf2 is a key transcription factor mediating anti-inflammatory and antioxidant responses in the body. Keap1 is a well-known repressor of Nrf2 that targets Nrf2 for its rapid proteasomal degradation. Dysfunctional Keap1-Nrf2 axis contributes to...
Published: 5/10/2021   |   Inventor(s): Longqin Hu, Dhulfiqar Abed
Keywords(s): Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Small Molecule Inhibitors of MIF for Inflammatory Diseases
Small molecules targeting to the inflammatory cytokine MIF could be a treatment for various diseases Invention Summary: A wide range of diseases can be addressed by targeting inflammatory cytokines. Although there are monoclonal antibody drugs that target, e. g., Tumor Necrosis Factor (TNF), no orally administrable small molecule inhibitor...
Published: 3/31/2021   |   Inventor(s): Spencer Knapp, Achyutharao Sidduri
Keywords(s): Autoimmune, Inflammation, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences
Novel Zinc Metallochaperone (ZMC) Complexes for Treatment of p53-Mutated Cancers
A) Novel mechanism of action: a short exposure to ZMCs increases zinc levels in tumors enough to restore normal structure/function to mutant p53 which leads to p53 mediated cancer cell death. B) Novel formulation: Synthesizing ZMCs as a zinc-loaded complex (Zn-1) improves survival in a pancreatic cancer mouse model compared to the ZMC compound alone....
Published: 1/26/2021   |   Inventor(s): Spencer Kimball, Darren Carpizo, John Gilleran
Keywords(s): Anti-cancer, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Novel Zinc Metallochaperone (ZMC) Complexes for Treatment of p53-Mutated Cancers
A) Novel mechanism of action: a short exposure to ZMCs increases zinc levels in tumors enough to restore normal structure/function to mutant p53 which leads to p53 mediated cancer cell death. B) Novel formulation: Synthesizing ZMCs as a zinc-loaded complex (Zn-1) improves survival in a pancreatic cancer mouse model compared to the ZMC compound alone....
Published: 1/26/2021   |   Inventor(s): Spencer Kimball, Darren Carpizo, John Gilleran
Keywords(s): Anti-cancer, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Novel Zinc Metallochaperone (ZMC) Complexes for Treatment of p53-Mutated Cancers
A) Novel mechanism of action: a short exposure to ZMCs increases zinc levels in tumors enough to restore normal structure/function to mutant p53 which leads to p53 mediated cancer cell death. B) Novel formulation: Synthesizing ZMCs as a zinc-loaded complex (Zn-1) improves survival in a pancreatic cancer mouse model compared to the ZMC compound alone....
Published: 1/26/2021   |   Inventor(s): Darren Carpizo, David Augeri, Spencer Kimball, Xin Yu
Keywords(s): Anti-cancer, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Prodrugs and ADC Derivatives of Non-Camptothecin TOP1-Targeting Cancer Chemotherapeutics
Schematic Structure of an Antibody-Drug Conjugate (ADC) (en.wikipedia.org) Invention Summary: Topoisomerase 1 (Top1) is an essential enzyme in mammalian cells and is a validated target for the treatment of human cancers. Topotecan and irinotecan (camptothecin analogues) are two FDA approved Top1-targeted drugs. Despite being powerful anticancer drugs,...
Published: 3/13/2019   |   Inventor(s): Edmond LaVoie, Ajit Parhi
Keywords(s): Anti-cancer, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics